Shares of Heron Therapeutics have been halted for trading, pending news, ahead of an expected decision from the FDA on the company’s new drug application, or NDA, for HTX-019 for Postoperative Nausea and Vomiting, or PONV. The NDA for HTX-019 for PONV was submitted in November 2021 and the FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of September 17, the company states on the pipeline page of its website.